Aquestive Therapeutics, Inc. AQST Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$8.06M+64.9% | -$31.86M-86.8% | -$15.45M-34.2% | -$13.55M-394% | -$22.93M-78.7% | ||
| $113K-18.7% | $130K-11.6% | $139K-12.6% | $140K-31.7% | $139K-32.9% | ||
| $2.32M+46.1% | $1.38M-42.7% | $2.78M+76.1% | $1.88M+22.4% | $1.59M+0.4% | ||
| $2.29M-16.9% | $2.75M+1.9% | $2.75M+2.8% | $2.75M+3.0% | $2.75M+2.9% | ||
| $1.9M+64.3% | —— | —— | $927K+221% | $1.15M+19.6% | ||
| -$17.97M-1,043% | $19.25M+630% | —— | —— | $1.91M+48.4% | ||
| -$2.8M-1.0% | $5.09M— | —— | —— | -$2.78M-48.2% | ||
| $340K+180% | —— | —— | -$2.68M-26.2% | -$423K-267% | ||
| -$6K+87.0% | -$1K+97.0% | -$11K+78.8% | $57K— | -$46K-43.8% | ||
| -$272K-4.2% | -$272K-4.2% | -$273K+81.7% | —— | -$261K+32.7% | ||
| -$10.9M-448% | $5.96M+357% | $0-100% | $1.35M+158% | $3.13M+2,229% | ||
| -$14.81M+36.7% | -$8.47M-30.5% | -$12.65M-6.5% | -$7.91M-13.0% | -$23.4M-125% | ||
| $52K-61.5% | $85K+467% | $235K+194% | $107K+206% | $135K+366% | ||
| -$52K+61.5% | -$85K-467% | -$235K-194% | -$107K-206% | -$135K-366% | ||
| $8K+33.3% | —— | —— | —— | $6K+4.3% | ||
| $1K— | $924K— | $339K+75.6% | $7K— | $0-100% | ||
| $329K-53.2% | $18K+1,700% | $70K-65.3% | $19K+280% | $703K-21.3% | ||
| $4.42M-78.6% | $660K+320% | $81.41M— | $0-100% | $20.65M-74.7% | ||
| -$10.44M-261% | —— | $68.53M— | -$8.12M— | -$2.89M-104% | ||
| $1.52M-0.1% | $1.52M-0.5% | $1.52M-49.8% | $1.53M0.0% | $1.53M+52.0% | ||
| $2.29M-16.9% | $2.75M+1.9% | $2.75M+2.8% | $2.75M+3.0% | $2.75M+2.9% | ||
| -$10.9M-448% | $5.96M+357% | $0-100% | $1.35M+158% | $3.13M+2,229% | ||
| -$2.8M-1.0% | $5.09M— | —— | —— | -$2.78M-48.2% | ||
| -$272K-4.2% | -$272K-4.2% | -$273K+81.7% | —— | -$261K+32.7% | ||
| $340K+180% | —— | —— | -$2.68M-26.2% | -$423K-267% | ||
| $916K— | —— | —— | —— | $0— | ||
| -$6K+87.0% | -$1K+97.0% | -$11K+78.8% | $57K— | -$46K-43.8% | ||
| $0-100% | —— | —— | —— | $5K+300% | ||
| $4.76M-77.7% | —— | —— | —— | $21.36M+625% | ||
| $8K+33.3% | —— | —— | —— | $6K+4.3% | ||
| $0-100% | —— | —— | —— | $89K— | ||
| —— | $16.25K— | $16.25K— | $16.25K— | $16.25K— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$14.86M+36.9% | -$8.55M-31.5% | -$12.88M-7.7% | -$8.02M-13.9% | -$23.54M-126% | ||
| -$14.86M+36.9% | -$8.55M-31.5% | -$12.88M-7.7% | -$8.02M-13.9% | -$23.54M-126% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aquestive Therapeutics, Inc. generate?
- Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
- Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
